Fred Hutch Cancer Center | Strategic Alliance Partners

April 29, 2024

Stacey Cohen, MD, discusses the rationale and study design of the phase 2/3 CIRCULATE-NORTH AMERICA study evaluating adjuvant chemotherapy selection based on MRD, and the panel discusses barriers to enrollment.

April 29, 2024

The panel continues its review of data presented on MRD testing in colorectal cancer from the INTERCEPT and COSMOS-CRC-01 studies.

April 23, 2024

The panel reviews recent data on MRD testing in colorectal cancer, highlighting the INTERCEPT and COSMOS-CRC-01 studies.

April 23, 2024

Benjamin A. Weinberg, MD, presents the case of a 35-year-old man with oligometastatic disease, and the panel provides insights on treatment decisions.

April 15, 2024

Pashtoon Murtaza Kasi, MD, MS, emphasizes key aspects of liquid biopsy and ctDNA testing in the MRD treatment landscape.

April 15, 2024

Pashtoon Murtaza Kasi, MD, MS, reviews data from the BESPOKE CRC study, highlighting overall results and patient-reported outcomes.

April 12, 2024

Petros Grivas, MD, PhD, discusses frontline treatment options for patients with metastatic renal cell carcinoma.

April 09, 2024

Focusing on the GALAXY arm in the CIRCULATE-Japan study, experts on colorectal cancer discuss how recent data are informing the evolving treatment landscape.

April 04, 2024

Petros Grivas, MD, PhD, discusses potential future directions for adjuvant therapies in patients with resected renal cell carcinoma.

April 01, 2024

John L. Marshall, MD, presents the case of a 52-year-old woman with mid-rectal carcinoma, and the panel offers its initial impressions.

April 01, 2024

The panel discusses how MRD testing has evolved as a clinical tool in colorectal cancer, highlighting the phase 2/3 COBRA study and its implications.

April 01, 2024

Elizabeth Plimack, MD, MS, FASCO, recaps the discussion with key takeaways on recent updates in bladder cancer.

March 25, 2024

Experts on colorectal cancer discuss practical considerations related to MRD testing, highlighting strategies to navigate potential challenges.

March 25, 2024

Pashtoon Murtaza Kasi, MD, MS, discusses MRD testing practices in the community oncology setting and provides recommendations on the integration of MRD testing into clinical practice.

March 25, 2024

Experts on bladder cancer discuss exciting new agents and treatment strategies and where they can potentially fit into urothelial cancer treatment paradigms.

March 25, 2024

Focusing on metastatic urothelial carcinoma, the panel discusses the role of chemotherapy and outlines treatment sequencing approaches.

March 18, 2024

Evan Y. Yu, MD, provides insights on treatment approaches for patients with metastatic urothelial carcinoma in the second line and beyond.

March 18, 2024

The expert panel discusses how treatment strategies change based on cisplatin eligibility and the role of maintenance therapy in metastatic urothelial carcinoma.

March 18, 2024

Focusing on the adjuvant setting, the expert panel discusses the timing and frequency of MRD testing in patients with colorectal cancer.

March 18, 2024

Colorectal cancer specialists discuss MRD testing platforms and how to choose among the available testing assays.